Skip to content
Oleogum Resin Extract / 5-Lipoxygenase Inhibitor

Boswellia Serrata

Frankincense resin, and the one common joint supplement that works on a branch of the inflammatory cascade nothing else in the cabinet touches. Boswellic acids inhibit 5-lipoxygenase and the leukotriene arm — which is why boswellia complements curcumin rather than duplicating it, and why the two are usually sold together.

anti-inflammatoryrecoverylongevity
Tier AWell-tolerated — strong human evidence
Evidence gradeBControlled trials / Cohort studies
BH

Reviewed & fact-checked by

BiohackingHub Research Team

Editorial Research Team · Last updated: August 10, 2026

Verified

What Boswellia Does That Others Don't

Arachidonic acid leaves the cell membrane and takes one of two roads. The cyclooxygenase road produces prostaglandins — the target of NSAIDs and, indirectly, of curcumin. The 5-lipoxygenase road produces leukotrienes, and almost nothing in an ordinary supplement stack touches it.

Boswellic acids do. AKBA — acetyl-11-keto-β-boswellic acid — is a direct 5-LOX inhibitor, and it is the reason boswellia belongs in an anti-inflammatory protocol alongside curcumin rather than as an alternative to it. Two extracts hitting two different enzymes in the same cascade is a genuine combination; two antioxidant polyphenols are usually just a more expensive version of one.

Boswellic acids also interfere with microsomal prostaglandin E synthase-1 and with cathepsin G, a neutrophil protease involved in tissue breakdown.

The Evidence

Knee osteoarthritis is where boswellia has been tested most rigorously. A systematic review and meta-analysis of oleogum resin extracts in knee osteoarthritis found improvements in pain and function across randomised trials.

A subsequent network meta-analysis compared Curcuma longa, Boswellia serrata, and mixed formulations head to head in knee osteoarthritis — the analysis that actually addresses whether the popular combination product beats its components.

Effect sizes are moderate and trial durations are short, typically four to twelve weeks. Boswellia is a credible option for joint symptoms, not a disease-modifying agent.

Inflammatory bowel disease and asthma appear frequently in boswellia marketing on the strength of the leukotriene mechanism, which is legitimately interesting — leukotrienes matter in both. The human trials remain small and preliminary.

Standardisation Is the Whole Game

Boswellia labels are inconsistent in ways that make products hard to compare:

Label claimWhat it means
"Boswellia serrata extract 400 mg"Meaningless without a standardisation figure
"65% boswellic acids"Total boswellic acids — the common baseline standard
"10% AKBA" (5-Loxin, Aflapin)The active fraction is specified — the more useful spec
"AKBA 100 mg"The clearest labelling; matches the enriched-extract trials

AKBA is the fraction with the 5-LOX activity, and it is a minor constituent of the crude resin. A cheap high-milligram extract with no AKBA figure may deliver less active compound than a smaller enriched dose.

Practical target: 100–250 mg/day of an AKBA-enriched extract, or 300–400 mg two to three times daily of an extract standardised to 65% boswellic acids, taken with food.

Safety

Boswellia is well tolerated. Gastrointestinal complaints — nausea, reflux, loose stools — are the usual limit, and notably it lacks the gastric mucosal damage that comes with COX-1 inhibition, which is much of the appeal for people who cannot take NSAIDs continuously.

Avoid in pregnancy on traditional-use and insufficient-data grounds. Flag it before surgery alongside other supplements with antiplatelet potential.

Related Research

Stacking Interactions

How Boswellia Serrata interacts with other compounds

+
Synergistic

The standard pairing, and mechanistically justified: curcumin hits NF-κB and COX-2, boswellia hits 5-LOX. A network meta-analysis in knee osteoarthritis compared the mixed formulation against each alone

+
Synergistic

Both act on lipid mediators — omega-3 shifts the substrate pool, boswellia blocks the enzyme that turns it into leukotrienes

+
Synergistic

Blocking production and actively resolving what is already there are complementary strategies, not competing ones

=
Neutral

Frequently combined for joints; different targets — structural substrate versus inflammatory signalling

Protocols using Boswellia Serrata

Evidence-graded stacks that include this compound

Safety Profile — Tier A

Well-tolerated — strong human evidence

Contraindications

  • Pregnancy — traditional emmenagogue use and insufficient modern data
  • Known hypersensitivity to Burseraceae resins

Side Effects

  • Mild gastrointestinal complaints: nausea, reflux, loose stools
  • Skin rash reported occasionally

Drug Interactions

Possible additive effect with NSAIDs and other anti-inflammatories (usually the intent)Theoretical interaction with CYP-metabolised drugs; clinically documented cases are scarceAnticoagulants — modest antiplatelet signal, worth flagging before surgery